BiotechTube
Home/Pipeline/LOAd703 (LOKON001)

LOAd703 (LOKON001)

Pancreatic Cancer

Phase 1/2Completed

Key Facts

Indication
Pancreatic Cancer
Phase
Phase 1/2
Status
Completed
Company
Lokon Pharma

About Lokon Pharma

Lokon Pharma is a clinical-stage biotech company pioneering immunostimulatory gene therapy for oncology. Its lead platform, the LOAd family of oncolytic adenoviruses, is engineered to modify the tumor microenvironment and stimulate anti-cancer immunity. The company has completed multiple Phase I/II trials in pancreatic cancer, melanoma, and other solid tumors, and has secured strategic collaborations with major pharmaceutical players like Roche. Lokon is positioning its lead candidate, LOAd703, for later-stage development, supported by FDA Fast Track Designation in pancreatic cancer.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b